Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled Phase 2a Trial of Efficacy and Safety of Evolocumab for PCSK9 Lowering in Early Acute Sepsis

NCT03869073 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.

NCT NCT03869073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03869073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled Phase 2a Trial of Efficacy and Safety of Evolocumab for PCSK9 Lowering in Early Acute Sepsis
Lead sponsor
University of British Columbia
Phase
Phase 2
Overall status
Unknown status
Start date
February 11, 2019
Completion date
February 11, 2021
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis